Comparing Injection Site Reactions of Aprepitant and Fosaprepitant in Gynecologic Cancer Chemotherapy

• Published in: In vivo (Athens) Vol. 38; no. 5; pp. 2374 - 2382
• Main Authors: Nishibe-Toyosato, Seira, Ando, Yosuke, Torii, Yutaka, Ichikawa, Ryoko, Owaki, Akiko, Miyamura, Hironori, Nishio, Eiji, Matsuda, Hidezo, Tsujii-Fujii, Naho, Shimato-Isobe, Akane, Mukaiji, Kotone, Ito, Kaori, Hayashi, Takahiro, Fujii, Takuma, Yamada, Shigeki
• Format: Journal Article
• Language: English
• Published: Greece 01.09.2024
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Aprepitant - administration & dosage; Female; Genital Neoplasms, Female - drug therapy; Humans; Middle Aged; Morpholines - administration & dosage; paclitaxel; carboplatin; bevacizumab; injection site reaction; Fosaprepitant meglumine; visual infusion phlebitis; gynecological cancer
• ISSN: 0258-851X; 1791-7549; 1791-7549
• DOI: 10.21873/invivo.13704

The frequency rate of injection site reactions (ISR) due to fosaprepitant meglumine (Fos APR) has been shown to vary depending on the types of combined anticancer drug. This study aimed to elucidate the impact of Fos APR on ISR in patients receiving paclitaxel and carboplatin, with and without bevacizumab therapy (TC±Bev). This study focused on patients with gynecologic cancer (n=93) who received TC±Bev administration at Fujita Health University Hospital from March 2016 to February 2020, and monitored up to six cycles. The patients were randomly assigned to the Fos APR group (n=47) and the Aprepitant (APR) group (n=46). Using Visual Infusion Phlebitis (VIP) scores, ISR was evaluated by comparing the VIP scores of all cycles using a linear mixed model. The risk factors that contribute to the occurrence of vascular pain throughout all cycles were also examined. The VIP scores of all cycles showed a near significant intergroup difference (p=0.071). Factors that affected the development of vascular pain included Fos APR and age (p=0.027 and 0.049, respectively). Regarding age, patients aged <65 years had a higher risk. Four patients underwent a switch from the originally assigned neurokinin-1 receptor antagonist; in all of these cases, Fos APR was changed to APR for vascular pain. Fos APR may increase the risk for ISR associated with TC±Bev therapy for gynecological cancer.